ArticleTheranostics2020
An ultrasensitive hybridization chain reaction-amplified CRISPR-Cas12a aptasensor for extracellular vesicle surface protein quantification.
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer.Frontiers in immunology · 2022Pooled it
- Bioinformatics mining and clinical validation of CD274 as a prognostic indicator in hepatocellular carcinoma.BMC cancer · 2026Article
- Exosomes liquid biopsy in Lymphoma precision medicine: applications and challenges.Cancer cell international · 2026Review
- Development of a one-tube PAM-independent RCNPM platform using Cas12a for ultra-rapid simultaneous miR-499 and cTnT detection in early acute myocardial infarction diagnosis.Journal of translational medicine · 2026Article
- Advanced Technologies in Extracellular Vesicle Biosensing: Platforms, Standardization, and Clinical Translation.Molecules (Basel, Switzerland) · 2026Review
- Review
- Extracellular Vesicles for Clinical Diagnostics: From Bulk Measurements to Single-Vesicle Analysis.ACS nano · 2025Review
- Exosomes in ovarian cancer: Impact on drug resistance and advances in SERS detection techniques.Journal of pharmaceutical analysis · 2025Review
- Synthetic biology meets Aspergillus: engineering strategies for next-generation organic acid production.World journal of microbiology & biotechnology · 2025Review
- Recent progress in prompt molecular detection of liquid biopsy using Cas enzymes: innovative approaches for cancer diagnosis and analysis.Journal of translational medicine · 2024Review
- CRISPR/Cas-mediated "one to more" lighting-up nucleic acid detection using aggregation-induced emission luminogens.Nature communications · 2024Article
- Recent advances in chemical biology tools for protein and RNA profiling of extracellular vesicles.RSC chemical biology · 2024Review
- Ultrasensitive ImmunoMag-CRISPR Lateral Flow Assay for Point-of-Care Testing of Urinary Biomarkers.ACS sensors · 2024Article
- A novel model for predicting prognosis and response to immunotherapy in nasopharyngeal carcinoma patients.Cancer immunology, immunotherapy : CII · 2024Article
- Combination of nucleic acid amplification and CRISPR/Cas technology in pathogen detection.Frontiers in microbiology · 2024Review
- From biogenesis to aptasensors: advancements in analysis for tumor-derived extracellular vesicles research.Theranostics · 2024Review
- Colorimetric aptasensor coupled with a deep-learning-powered smartphone app for programmed death ligand-1 expressing extracellular vesicles.Frontiers in immunology · 2024Article
- Recent advances and challenges of the use of the CRISPR/Cas system as a non-nucleic acid molecular diagnostic.Heliyon · 2023Review
- Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology.Biomarker research · 2023Review
- CRISPR-based diagnostics of different biomolecules from nucleic acids, proteins, and small molecules to exosomes.Acta biochimica et biophysica Sinica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-derived extracellular vesicle (TEV) protein biomarkers facilitate cancer diagnosis and prognostic evaluations. However, the lack of reliable and convenient quantitative methods for evaluating TEV proteins prevents their clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.